Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from AstraZeneca.
Oncology Best Practice™: Working Group to Optimize Outcomes in EGFR-Mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient Care
In order to request this CME/CE activity for your center, please contact Samantha Miller at firstname.lastname@example.org or call (609) 325-4668
Oncology Best Practice™:
Working Group to Optimize Outcomes in EGFR-Mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient Care
The fast pace of developments in the management of patients with non–small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) gene has challenged practitioners to maintain state-of-the-art practices with regard to choosing therapy, monitoring for resistance, and discussing adverse event management and adherence to therapy with their patients. Advances in the field will continue to emerge in 2017, and these will create knowledge and/or practice gaps for oncology-focused nurses who strive to optimize care for their patients.
To meet these medical needs, this series of Oncology Best Practice™ will provide oncology nurses and other oncology healthcare professionals who participate in the multidisciplinary treatment of patients with EGFR-mutated NSCLC with practical approaches to managing clinical challenges with this group of patients with lung cancer. These 1-hour interactive meetings will feature nationally renowned experts in oncology nursing, who will travel directly to leading cancer centers, large oncology practice groups, and community hospitals throughout the United States.
Key topics to be addressed by faculty include:
- Practice-changing clinical data with EGFR inhibitors
- Choosing the optimal therapeutic approach through multiple lines of therapy
- Expert guidance on how to proactively mitigate and manage treatment-related toxicities
- Novel molecular testing approaches, including the use of liquid biopsies
- Counseling patients awaiting molecular testing results
- Ensuring compliance with oral therapeutic regimens
Ample discussion time will also allow participants to interact with expert faculty to address challenges they face in their everyday practice.
This educational activity is directed toward nurses and other healthcare professionals with an interest in the treatment of lung cancers.
At the conclusion of this activity, participants should be better prepared to:
- Explain current and emerging testing platforms in the context of novel methods to overcome barriers associated with tumor biopsies in the field of lung cancer treatment
- Detail key counseling points to address with patients with lung cancer who are awaiting results from tumor tissue testing
- Describe current and emerging evidence concerning the use of EGFR-targeted strategies in frontline and relapsed advanced NSCLC disease settings
- Apply nursing best practices to counsel patients with advanced NSCLC concerning the prevention, mitigation, and management of treatment-related toxicities
Ben Levy, MD
Associate Professor, Johns Hopkins Medicine
Clinical Director, Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Karen C. Lee, MSN, FNP-BC
Thoracic Oncology Program
Mount Sinai Health System
New York, NY